Exhibit 99.2
Elicio Corporate Twitter Post, April 27, 2023, 5:17 AM
We're pleased to announce that the first patient has been dosed with the 7P formulation of our investigational therapeutic #cancervaccine, which targets seven of the most common #KRAS/NRAS mutations. Learn more about our technology and the trial here: https://bit.ly/3n7k6Nk
![imagea.jpg](https://capedge.com/proxy/8-K/0001601485-23-000021/imagea.jpg)